Chen Yishan, Yi Jingsong, Lin Shunhe, Xie Xi, Liu Xishi, Guo Sun-Wei
Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian 350001, China.
Department of Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.; Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Fudan University, Shanghai, China.
Reprod Biomed Online. 2025 Jan;50(1):104436. doi: 10.1016/j.rbmo.2024.104436. Epub 2024 Sep 3.
Does high-intensity focused ultrasound (HIFU) ablation have comparable reproductive outcomes to myomectomy for patients with uterine fibroids?
A systematic review and a meta-analysis of data extracted from published studies up to March 2024.
Through a more structured analysis, HIFU treatment yielded a pooled pregnancy rate of 23.3% (95% CI 11.5 to 37.6%) and a pooled live birth rate (LBR) of 17.3% (95% CI 7.8 to 29.3%), significantly lower than those after myomectomy, which had a pooled pregnancy rate of 56.9% (95% CI 45.6 to 67.9%) and a pooled LBR of 44.1% (95% CI 34.9 to 53.4%) (P = 0.0001 and P = 0.0003, respectively). After controlling for patient age, ultrasound-guided HIFU studies reported significantly lower pregnancy rate and LBR compared with myomectomy. Moreover, studies enrolling younger patients and explicitly recruiting those desiring to conceive reported better reproductive outcomes.
Patients with uterine fibroids undergoing HIFU treatment and desiring to preserve their uteri resulted in poorer reproductive outcomes compared with myomectomy. Although uterine fibroids are now the number one disease that receives HIFU treatment worldwide, the overall quality in design and execution of HIFU studies on reproductive outcomes for women with uterine fibroids leaves much room for improvement. Above all, comparative trials against the standard of care are badly needed.
对于子宫肌瘤患者,高强度聚焦超声(HIFU)消融术的生殖结局与子宫肌瘤切除术是否相当?
对截至2024年3月发表的研究中提取的数据进行系统评价和荟萃分析。
通过更结构化的分析,HIFU治疗的合并妊娠率为23.3%(95%CI 11.5%至37.6%),合并活产率(LBR)为17.3%(95%CI 7.8%至29.3%),显著低于子宫肌瘤切除术后的合并妊娠率56.9%(95%CI 45.6%至67.9%)和合并LBR 44.1%(95%CI 34.9%至53.4%)(P分别为0.0001和0.0003)。在控制患者年龄后,超声引导下的HIFU研究报告的妊娠率和LBR显著低于子宫肌瘤切除术。此外,纳入年轻患者并明确招募有生育意愿者的研究报告了更好的生殖结局。
与子宫肌瘤切除术相比,接受HIFU治疗且希望保留子宫的子宫肌瘤患者生殖结局较差。尽管子宫肌瘤目前是全球接受HIFU治疗的头号疾病,但关于子宫肌瘤女性生殖结局的HIFU研究在设计和实施方面的整体质量仍有很大改进空间。最重要的是,急需开展对照标准治疗的对比试验。